ImmuneXcite is developing a diseaseĀ and cancer therapy by enhancing the efficacy of therapeutic monoclonal antibodies for oncological and infectious disease targets.

This company is a spinout of the 2007 project, Compound to Enhance Immune Stimulation.

Watch the CSO and co-founder, Ifat Rubin-Bejerano, present the ImmunExcite story at IdeaStream 2015 below.